Wall Street analysts expect PetIQ Inc (NASDAQ:PETQ) to report $168.90 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for PetIQ’s earnings, with the lowest sales estimate coming in at $165.51 million and the highest estimate coming in at $171.30 million. PetIQ posted sales of $186.03 million in the same quarter last year, which would indicate a negative year over year growth rate of 9.2%. The company is scheduled to issue its next quarterly earnings report on Thursday, November 5th.

According to Zacks, analysts expect that PetIQ will report full-year sales of $789.73 million for the current year, with estimates ranging from $781.70 million to $798.90 million. For the next fiscal year, analysts anticipate that the business will post sales of $917.95 million, with estimates ranging from $889.30 million to $978.43 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for PetIQ.

PetIQ (NASDAQ:PETQ) last released its earnings results on Thursday, August 6th. The company reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.26. The firm had revenue of $266.98 million during the quarter, compared to analysts’ expectations of $251.20 million. PetIQ had a negative net margin of 2.63% and a positive return on equity of 8.52%.

A number of equities analysts have weighed in on PETQ shares. Guggenheim lifted their target price on shares of PetIQ from $130.00 to $175.00 in a report on Monday, August 17th. BidaskClub lowered shares of PetIQ from a “buy” rating to a “hold” rating in a report on Wednesday, September 9th. Zacks Investment Research upgraded shares of PetIQ from a “sell” rating to a “hold” rating in a report on Wednesday, October 7th. Raymond James cut their price objective on shares of PetIQ from $44.00 to $43.00 and set an “outperform” rating on the stock in a report on Friday, August 14th. Finally, Oppenheimer reiterated a “buy” rating and issued a $50.00 price objective on shares of PetIQ in a report on Friday, August 7th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $69.00.

Shares of PETQ traded up $0.03 during mid-day trading on Thursday, reaching $32.61. The company had a trading volume of 193,717 shares, compared to its average volume of 380,257. The stock has a market cap of $931.73 million, a price-to-earnings ratio of -36.23, a price-to-earnings-growth ratio of 1.81 and a beta of 1.55. The firm has a fifty day simple moving average of $32.55 and a 200-day simple moving average of $30.68. PetIQ has a fifty-two week low of $15.83 and a fifty-two week high of $38.99. The company has a current ratio of 3.06, a quick ratio of 2.17 and a debt-to-equity ratio of 1.04.

Large investors have recently made changes to their positions in the stock. Fifth Third Bancorp bought a new stake in shares of PetIQ during the 2nd quarter valued at about $40,000. Private Advisor Group LLC bought a new stake in shares of PetIQ during the 2nd quarter valued at about $105,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of PetIQ by 99.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,944 shares of the company’s stock valued at $137,000 after buying an additional 1,971 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in shares of PetIQ by 162.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,149 shares of the company’s stock valued at $143,000 after buying an additional 3,810 shares during the last quarter. Finally, Xcel Wealth Management LLC acquired a new position in PetIQ during the 2nd quarter valued at about $227,000.

About PetIQ

PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.

Read More: G-20

Get a free copy of the Zacks research report on PetIQ (PETQ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.